表 1.
大出血组与非大出血组的临床病理特征比较
Comparison of clinicopathological characteristics between massive hemorrhage group and non-massive hemorrhage group
| Items | Non-massive hemorrhage group (n=181) | Massive hemorrhage group (n=60) | P |
| BMI, body mass index; ASA, American Society of Anesthesiologists; M, metastasis; IVC, inferior vena cava. *P < 0.05. | |||
| Gender, n (%) | 0.488 | ||
| Male | 136 (75.1) | 48 (80.0) | |
| Female | 45 (24.9) | 12 (20.0) | |
| Age/years, M (P25, P75) | 59 (53, 66) | 62 (54, 68) | 0.122 |
| Clinical symptoms, n (%) | 0.175 | ||
| None | 44 (24.3) | 9 (15.0) | |
| Local symptoms | 93 (51.4) | 31 (51.7) | |
| Systematic symptoms | 16 (8.8) | 4 (6.7) | |
| Both | 28 (15.5) | 16 (26.7) | |
| BMI/(kg/m2), M (P25, P75) | 23.3 (21.1, 25.8) | 24.3 (21.4, 26.1) | 0.107 |
| Surgical approach, n (%) | < 0.001* | ||
| Laparoscopic surgery | 118 (65.2) | 10 (16.7) | |
| Open | 63 (34.8) | 50 (83.3) | |
| Mayo classification, n (%) | < 0.001* | ||
| 0 | 56 (30.9) | 4 (6.7) | |
| 1 | 40 (22.1) | 2 (3.3) | |
| 2 | 63 (34.8) | 28 (46.7) | |
| 3 | 16 (8.9) | 11 (18.3) | |
| 4 | 6 (3.3) | 15 (25.0) | |
| ASA grade, n (%) | 0.001* | ||
| 1 | 16 (8.8) | 0 (0) | |
| 2 | 146 (80.7) | 45 (75.0) | |
| 3 | 19 (10.5) | 15 (25.0) | |
| Preoperative serum creatinine/(μmol/L), | 91 (80.5, 107) | 93 (81, 112) | 0.431 |
| M (P25, P75) | |||
| Preoperative hemoglobin/(g/L), M (P25, P75) | 124 (109.5, 139.5) | 113 (97, 125) | ＜0.001* |
| Preoperative neutrophil/(×109/L), M (P25, P75) | 4.5 (3.4, 5.5) | 4.4 (3.7, 5.1) | 0.754 |
| Preoperative lymphocyte/(×109/L), M (P25, P75) | 1.3 (1.0, 1.6) | 1.2 (0.9, 1.5) | 0.043* |
| Preoperative monocyte/(×109/L), M (P25, P75) | 0.4 (0.3, 0.5) | 0.4 (0.3, 0.5) | 0.422 |
| Preoperative platelet/(×109/L), M (P25, P75) | 241 (189.0, 303.5) | 213 (167.0, 291.0) | 0.033* |
| Lesion side, n (%) | 0.646 | ||
| Left | 66 (36.5) | 24 (40.0) | |
| Right | 115 (63.5) | 36 (60.0) | |
| Tumor diameter/cm, M (P25, P75) | 8.8 (6.7, 10.5) | 8.7 (6.8, 10.9) | 0.786 |
| Maximum tumor thrombus width/mm, M (P25, P75) | 20 (15, 30) | 30 (20, 35) | ＜0.001* |
| Clinical phase of M, n (%) | 0.669 | ||
| M0 | 126 (69.6) | 40 (66.7) | |
| M1 | 55 (30.4) | 20 (33.3) | |
| Complicated with bland thrombus, n (%) | < 0.001* | ||
| No | 159 (87.8) | 37 (61.7) | |
| Yes | 22 (12.2) | 23 (38.3) | |
| Adrenalectomy, n (%) | 0.011* | ||
| No | 92 (50.8) | 15 (25.0) | |
| Yes | 89 (49.2) | 45 (75.0) | |
| Segmental resection of IVC, n (%) | 0.003* | ||
| No | 159 (87.8) | 43 (71.7) | |
| Yes | 22 (12.2) | 17 (28.3) | |
| Lymph node dissection, n (%) | 0.248 | ||
| No | 100 (55.2) | 28 (46.7) | |
| Yes | 81 (44.8) | 32 (53.3) | |
| Operation time/min, M (P25, P75) | 289 (218, 374) | 408 (342, 499) | ＜0.001* |
| Blood loss/mL, M (P25, P75) | 400 (150, 800) | 3 000 (2 250, 4 000) | ＜0.001* |
| Intraoperative infusion volume/mL, M (P25, P75) | 0 (0, 400) | 2 000 (1 300, 2 800) | ＜0.001* |
| Pathological type, n (%) | 0.854 | ||
| Clear cell carcinoma | 148 (81.7) | 52 (86.7) | |
| Papillary cell carcinoma | 22 (12.2) | 5 (8.3) | |
| Chromophobe cell carcinoma | 2 (1.1) | 0 (0) | |
| Unclassified cell carcinoma | 7 (3.9) | 3 (5.0) | |
| Xp11.2 cell carcinoma | 2 (1.1) | 0 (0) | |
| Nuclear classification, n (%) | 0.358 | ||
| 1 | 3 (1.7) | 0 (0) | |
| 2 | 68 (37.5) | 17 (28.3) | |
| 3 | 74 (40.9) | 26 (43.4) | |
| 4 | 36 (19.9) | 17 (28.3) | |
| Sarcomatoid features, n (%) | 0.128 | ||
| No | 160 (88.4) | 48 (80.0) | |
| Yes | 21 (11.6) | 12 (20.0) | |
| Perirenal fat infiltration, n (%) | 0.063 | ||
| No | 129 (71.3) | 35 (58.3) | |
| Yes | 52 (28.7) | 25 (41.7) | |
| Postoperative hospital stay/d, M (P25, P75) | 8 (6, 10) | 12 (8, 15) | ＜0.001* |
| Serum creatinine after one week/(μmol/L), M (P25, P75) |
98 (79.0, 115.5) | 93 (80.0, 121.0) | 0.799 |
| Postoperative complications, n (%) | ＜0.001* | ||
| No | 139 (76.8) | 18 (30.0) | |
| Yes | 42 (23.2) | 42 (70.0) | |
| Severe postoperative complications, n (%) | 0.016* | ||
| No | 173 (95.6) | 51 (85.0) | |
| Yes | 8 (4.4) | 9 (15.0) | |